search
Back to results

SpineJack® Versus Conservative Treatment Study (SPICO Study)

Primary Purpose

Spinal Fractures, Vertebral Compression Fractures, Back Injuries

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
SpineJack system
Conservative management
Sponsored by
Vexim SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Fractures

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient must have signed the consent form
  2. Male or Female between 18 and 60 years old
  3. One to two painful traumatic fractures, non-pathological, traumatic vertebral fracture is less than 10 days, between T11 and L5, type A1 and A3.1 according to Magerl classification. All the fractures should meet the inclusion criteria (deformity, etiology, technical possibility of performing the procedure).
  4. Vertebral kyphosis angle >10°
  5. Patient is eligible to treatment with brace
  6. Technical feasibility of a SpineJack® procedure and brace 1 to 5 days after screening/baseline

Exclusion Criteria:

  1. Vertebral fracture more than 10 days old
  2. Spontaneous osteoporotic vertebral fracture
  3. Neurological signs or symptoms related to the vertebral fracture
  4. Vertebral kyphosis angle >30°
  5. Active systemic or local infection at baseline
  6. Patient with substance abuse
  7. History of intolerance or allergic reaction to titanium or acrylic compounds
  8. Fracture geometry making the insertion of the implant impossible
  9. Malignant lesions
  10. Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery*
  11. Patient on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months)
  12. Patient presenting with a non-correctable spontaneous or therapeutic coagulation disorder.
  13. Non-compliant patient: Impossibility to participate in the study and to be followed-up for 2 years.
  14. Participating in any other investigational study
  15. Female patients who are pregnant, breastfeeding, or planning to get pregnant during the course of the study
  16. Patient not affiliated to social security *: including but not limited to patients with contraindications for general anesthesia (surgeon expertise)

Sites / Locations

  • Hopital Jean Minjoz Besancon
  • CHU de Bordeaux - Hopital Pellegrin
  • CHU Brest
  • Centre Hospitalier De Chambéry
  • CHU de Dijon
  • APHM, Hopital Nord Marseille
  • CHU de Rennes
  • CHU de Rouen-Hopital Charles Nicolle
  • Centre Hospitalier Privé Saint Grégoire

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

SpineJack® system

Conservative management

Arm Description

Spine fracture management

Surgical corset according to measurement's impression, rigid corset with sternal support

Outcomes

Primary Outcome Measures

VAS
Mean Visual Analogue Scale (VAS) back pain score at 1 and 12 months follow-up

Secondary Outcome Measures

Oswestry Disability Index
EQ-5D
Kyphotic angle
Regional Kyphotic Angle
Evaluation of safety through evaluation of adverse events
Costs comparison of overall treatments

Full Information

First Posted
January 5, 2016
Last Updated
April 17, 2023
Sponsor
Vexim SA
Collaborators
Statitec
search

1. Study Identification

Unique Protocol Identification Number
NCT02657265
Brief Title
SpineJack® Versus Conservative Treatment Study (SPICO Study)
Official Title
Prospective Multicenter Randomized Study Comparing Two Standard Treatments: SpineJack® System and Conservative Orthopedic Management in Acute Traumatic Vertebral Fractures Types A1 and A3.1 According to the Magerl Classification
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
January 13, 2016 (Actual)
Primary Completion Date
May 27, 2019 (Actual)
Study Completion Date
May 25, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vexim SA
Collaborators
Statitec

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will compare two standard treatments in acute stable traumatic vertebral fractures (types A1 and A3.1 by Magerl Classification). The two treatments are as follows: SpineJack® system Conservative Orthopedic Management consisting of brace and pain medication.
Detailed Description
100 subjects (18 to 60 years old) will be enrolled (1:1) with one to two painful traumatic fractures, non-pathological (types A1 and A3.1 by Magerl Classification). Subjects will be followed at admission, procedure, discharge, 1 month, 3 months, 12 months and 24 months post Vertebral Compression Fracture (VCF) reduction procedure or the set-up of the brace. The estimated enrollment period is 12 months and each patient should perform a 24 months follow-up period. Therefore, the total study duration is estimated to be 36 months for the complete study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Fractures, Vertebral Compression Fractures, Back Injuries, Trauma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SpineJack® system
Arm Type
Experimental
Arm Description
Spine fracture management
Arm Title
Conservative management
Arm Type
Active Comparator
Arm Description
Surgical corset according to measurement's impression, rigid corset with sternal support
Intervention Type
Device
Intervention Name(s)
SpineJack system
Intervention Description
Spine fracture management for traumatic vertebral compression fracture
Intervention Type
Device
Intervention Name(s)
Conservative management
Intervention Description
Surgical corset according to measurement's impression, rigid corset with sternal support
Primary Outcome Measure Information:
Title
VAS
Description
Mean Visual Analogue Scale (VAS) back pain score at 1 and 12 months follow-up
Time Frame
1 and 12 months follow-up
Secondary Outcome Measure Information:
Title
Oswestry Disability Index
Time Frame
Screening/baseline, immediat post-op, 1, 3, 12 and 24 months
Title
EQ-5D
Time Frame
Screening/baseline, immediat post-op, 1, 3, 12 and 24 months
Title
Kyphotic angle
Time Frame
Screening/baseline, immediat post-op, 1, 3, 12 and 24 months
Title
Regional Kyphotic Angle
Time Frame
Screening/baseline, immediat post-op, 1, 3, 12 and 24 months
Title
Evaluation of safety through evaluation of adverse events
Time Frame
Screening/baseline, immediat post-op, 1, 3, 12 and 24 months
Title
Costs comparison of overall treatments
Time Frame
Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient must have signed the consent form Male or Female between 18 and 60 years old One to two painful traumatic fractures, non-pathological, traumatic vertebral fracture is less than 10 days, between T11 and L5, type A1 and A3.1 according to Magerl classification. All the fractures should meet the inclusion criteria (deformity, etiology, technical possibility of performing the procedure). Vertebral kyphosis angle >10° Patient is eligible to treatment with brace Technical feasibility of a SpineJack® procedure and brace 1 to 5 days after screening/baseline Exclusion Criteria: Vertebral fracture more than 10 days old Spontaneous osteoporotic vertebral fracture Neurological signs or symptoms related to the vertebral fracture Vertebral kyphosis angle >30° Active systemic or local infection at baseline Patient with substance abuse History of intolerance or allergic reaction to titanium or acrylic compounds Fracture geometry making the insertion of the implant impossible Malignant lesions Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery* Patient on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months) Patient presenting with a non-correctable spontaneous or therapeutic coagulation disorder. Non-compliant patient: Impossibility to participate in the study and to be followed-up for 2 years. Participating in any other investigational study Female patients who are pregnant, breastfeeding, or planning to get pregnant during the course of the study Patient not affiliated to social security *: including but not limited to patients with contraindications for general anesthesia (surgeon expertise)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Marc Vital, Prof.
Organizational Affiliation
Hopital Pellegrin - Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital Jean Minjoz Besancon
City
Besançon
Country
France
Facility Name
CHU de Bordeaux - Hopital Pellegrin
City
Bordeaux
Country
France
Facility Name
CHU Brest
City
Brest
Country
France
Facility Name
Centre Hospitalier De Chambéry
City
Chambéry
Country
France
Facility Name
CHU de Dijon
City
Dijon
Country
France
Facility Name
APHM, Hopital Nord Marseille
City
Marseille
Country
France
Facility Name
CHU de Rennes
City
Rennes
Country
France
Facility Name
CHU de Rouen-Hopital Charles Nicolle
City
Rouen
Country
France
Facility Name
Centre Hospitalier Privé Saint Grégoire
City
Saint-Grégoire
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SpineJack® Versus Conservative Treatment Study (SPICO Study)

We'll reach out to this number within 24 hrs